FMC Stock Analysis: FMC | NYSE
Agricultural Inputs | NYSE, USA | Market Cap: 876m USD | 12M Return: -60.8% | US3024913036 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 44.4M
Qual. Beats: -1
Rev. Trend: -90.1%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
FMC Corporation is a global agricultural sciences company that develops, manufactures, and sells crop protection products across Latin America, North America, Europe, the Middle East, Africa, and Asia. Its product portfolio spans traditional synthetic chemistries-insecticides, herbicides, and fungicides-as well as biologicals, crop nutrition solutions, and seed treatments. The company distributes its products through a hybrid model combining its own sales force with alliance partners, independent distributors, and sales representatives.
The crop protection industry is highly R&D-intensive, as bringing a new active ingredient to market typically requires extensive regulatory review and significant investment, often exceeding $300 million and spanning 10+ years from discovery to commercialization. Demand for these products is driven by the need to maximize yields on existing arable land to feed a growing global population, while biologicals and seed treatments represent faster-growing sub-segments as farmers adopt integrated and more sustainable pest management practices.
Founded in 1883 and headquartered in Philadelphia, Pennsylvania, FMC has a long operating history in agricultural and industrial chemicals. Listed on the NYSE since 1985, the company operates within the Fertilizers & Agricultural Chemicals sub-industry of the broader Materials sector, competing alongside other major global agrochemical firms that serve the worlds large-scale commercial farming operations.
- Generic competition pressures pricing in Latin America crop protection
- Brazil real depreciation pressures reported revenue and margins
- Glyphosate patent litigation overhang weighs on valuation
| Net Income: -4.26b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 7.81 > 1.0 |
| NWC/Revenue: 63.42% < 20% (prev 44.35%; Δ 19.07% < -1%) |
| CFO/TA 0.04 > 3% & CFO 335.6m > Net Income -4.26b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (133.0m) vs 12m ago 6.31% < -2% |
| Gross Margin: 23.36% > 18% (prev 36.87%; Δ -13.51% > 0.5%) |
| Asset Turnover: 28.70% > 50% (prev 29.43%; Δ -0.74% > 0%) |
| Interest Coverage Ratio: -0.52 > 6 (EBIT TTM -869.7m / Interest Expense TTM 1.66b) |
| A: 0.23 (Total Current Assets 4.58b - Total Current Liabilities 2.76b) / Total Assets 7.91b |
| B: 0.18 (Retained Earnings 1.40b / Total Assets 7.91b) |
| C: -0.09 (EBIT TTM -869.7m / Avg Total Assets 9.99b) |
| D: -0.00 (Book Value of Equity -19.4m / Total Liabilities 7.90b) |
| Altman-Z'' = 1.50 = BB |
| DSRI: 0.92 (Receivables 1.72b/2.33b, Revenue 2.87b/3.56b) |
| GMI: 1.58 (GM 36.87% / 23.36%) |
| AQI: 0.77 (AQ_t 0.36 / AQ_t-1 0.47) |
| SGI: 0.81 (Revenue 2.87b / 3.56b) |
| TATA: -0.58 (NI -4.26b - CFO 335.6m) / TA 7.91b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of November 14, 2026, the stock is trading at USD 5.21 with a total of 4,925,995 shares traded. Over the past week, the price has changed by -7.46%, over one month by -37.30%, over three months by -48.27% and over the past year by -60.79%.
Current recommended Stop Loss: 4.50 (which is 13.6% or 1.2 ATR below the current price).
FMC has received a consensus analysts rating of 3.18. Therefore, it is recommended to hold FMC.
- StrongBuy: 3
- Buy: 0
- Hold: 12
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 7.7 | 46.8% |
P/E Forward = 4.5413
P/S = 0.3111
P/B = 101.5223
P/EG = 0.4579
Revenue TTM = 2.87b USD
EBIT TTM = -869.7m USD
EBITDA TTM = -619.0m USD
Long Term Debt = 3.95b USD (from longTermDebt, last quarter)
Short Term Debt = 251.5m USD (from shortTermDebt, last quarter)
Debt = 4.42b USD (from shortLongTermDebtTotal, last quarter) + Leases 123.9m
Net Debt = 3.68b USD (calculated: Debt 4.42b - CCE 735.8m)
Enterprise Value = 4.56b USD (875.8m + Debt 4.42b - CCE 735.8m)
Interest Coverage Ratio = -0.52 (Ebit TTM -869.7m / Interest Expense TTM 1.66b)
EV/FCF = 13.04x (Enterprise Value 4.56b / FCF TTM 349.8m)
FCF Yield = 7.67% (FCF TTM 349.8m / Enterprise Value 4.56b)
FCF Margin = 12.20% (FCF TTM 349.8m / Revenue TTM 2.87b)
Net Margin = -148.4% (Net Income TTM -4.26b / Revenue TTM 2.87b)
Gross Margin = 23.36% ((Revenue TTM 2.87b - Cost of Revenue TTM 2.20b) / Revenue TTM)
Gross Margin QoQ = none% (prev 39.45%)
Tobins Q-Ratio = 0.58 (Enterprise Value 4.56b / Total Assets 7.91b)
Interest Expense / Debt = 37.63% (Interest Expense 1.66b / Debt 4.42b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -687.1m (EBIT -869.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.66 (Total Current Assets 4.58b / Total Current Liabilities 2.76b)
Debt / Equity = -227.8 (out of range, set to none) (Debt 4.42b / totalStockholderEquity, last quarter -19.4m)
Debt / EBITDA = -5.95 (negative EBITDA) (Net Debt 3.68b / EBITDA -619.0m)
Debt / FCF = 10.53 (Net Debt 3.68b / FCF TTM 349.8m)
Total Stockholder Equity = 1.38b (last 4 quarters mean from totalStockholderEquity)
RoA = -42.58% (Net Income -4.26b / Total Assets 7.91b)
RoE = -308.9% (Net Income TTM -4.26b / Total Stockholder Equity 1.38b)
RoCE = -16.31% (EBIT -869.7m / Capital Employed (Equity 1.38b + L.T.Debt 3.95b))
RoIC = -13.06% (negative operating profit) (NOPAT -687.1m / Invested Capital 5.26b)
WACC = 26.40% (E(875.8m)/V(5.30b) * Re(9.62%) + D(4.42b)/V(5.30b) * Rd(37.63%) * (1-Tc(0.21)))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 50.02 | Cagr: 2.67%
[DCF] Terminal Value 34.59% ; FCFF base≈349.8m ; Y1≈351.2m ; Y5≈372.1m
[DCF] Fair Price = N/A (negative equity: EV 1.43b - Net Debt 3.68b = -2.25b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: -90.06 | Revenue CAGR: -12.55% | SUE: -1.67 | # QB: -1
EPS current Quarter (2027-03-31): EPS=-0.12 | Chg30d=-1.65% | Revisions=-17% | Analysts=8
EPS current Year (2026-12-31): EPS=-3.63 | Chg30d=-383.93% | Revisions=-57% | GrowthEPS=-222.7% | GrowthRev=-20.2%
EPS next Year (2027-12-31): EPS=0.95 | Chg30d=-40.68% | Revisions=-67% | GrowthEPS=+126.0% | GrowthRev=+25.0%
[Analyst] Revisions Ratio: -69% (up=1, down=12)